Figure 1: BRMS1L expression in breast tissues and cell lines.
From: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10
(a) Representative immunohistochemical staining of BRMS1L in normal breast tissue (normal), primary breast cancer with or without regional lymph node (LN) metastasis, metastatic lymph nodes (LNM) and brain metastases (BM). Scale bar corresponds to 50 μm. (b) The ratio of BRMS1L versus gyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA measured by qRT–PCR in normal breast tissue (normal; n=30), primary breast cancer with (n=30) or without regional LN metastasis (n=30), LNM (n=30) and liver metastases (LM; =30). Student’s t-test was used for the comparison of two independent groups. (c) Kaplan–Meier overall survival (OS) curve of patients with low (IRS≤4) and high (IRS>4) BRMS1L levels with a median follow-up period of 55 months. Log Rank Test was used to analyse survival differences. (d,e) mRNA and protein expression levels of BRMS1L measured by qRT–PCR (d) and western blotting (e) in various breast epithelial cell lines. Bars correspond to mean±s.d. These data are representative of three independent experiments.
